Non-Small Cell Lung Cancer Market: by Type (Squamous cell (epidermoid) carcinoma, Adenocarcinoma, Large cell (undifferentiated) carcinoma and Other), Therapy (Chemotherapy, Radiotherapy, Laser therapy, Photodynamic therapy (PDT) and Others) and Distribution Channel (Hospital pharmacies, Online pharmacies and Others) – Global Industry Perspective Comprehensive Analysis and Forecast, 2019-2025

Published Date: 02-Dec-2019 Category: Healthcare Report Format : PDF Pages: 130 Report Code: ZMR-5124 Status : Published

Global demand for Non-Small Cell Lung Cancer Market was valued at approximately USD 6381.46 Million in 2018, and is expected to generate revenue of around USD 10175.53 Million by end of 2025, growing at a CAGR of around 6.93% between 2018 and 2025.

Description

The report covers forecast and analysis for the Non-Small Cell Lung Cancer market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Non-Small Cell Lung Cancer market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Non-Small Cell Lung Cancer market on a global level. In order to give the users of this report a comprehensive view on the Non-Small Cell Lung Cancer market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein type, therapy, distribution channel, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

According to the report, global demand for Non-Small Cell Lung Cancer Market was valued at approximately USD 6381.46 Million in 2018, and is expected to generate revenue of around USD 10175.53 Million by end of 2025, growing at a CAGR of around 6.93% between 2018 and 2025.

Lung cancer is categorized as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in two forms. Lung cancer is uncontrolled lung tissue cell growth. Lung cancer's bulk is NSCLC. Common symptoms include chest pain, wheezing, blood vomiting, heaviness, weight loss, persistent bronchitis, loss of appetite, tiredness, shortness of breath, bone pain, trouble swallowing, and limb numbness. Increasing incidences of smoking-related lung cancer, air pollution (asbestos, cadmium, and radon), HIV infection, and population growth are few of NSCLC's growth factors.

The study provides a decisive view on the Non-Small Cell Lung Cancer market by segmenting the market based on Type, Therapy, Distribution Channel and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on Type, the market is segmented into        Squamous cell (epidermoid) carcinoma, Adenocarcinoma, Large cell (undifferentiated) carcinoma and Other. In any section of the lung, large cell carcinoma or undifferentiated form develops, rising fastest and is difficult to treat. Adenocarcinoma is the slowest growth compared to two other types and is found in the outer lungs cells responsible for mucous secretion.

Based on the Therapy segment, the market is bifurcated Chemotherapy, Radiotherapy, Laser therapy, Photodynamic therapy (PDT) and Others.  Based on the Distribution Channel segment, the market is bifurcated into Hospital pharmacies, Online pharmacies and Others. The distribution channel group for hospital pharmacies will have a significant share over the coming years. Hospital pharmacies typically store a large number of drugs and advanced equipment and provide hospital patients with medication. The burden of genetic disorder would increase the number of hospitalizations, thereby having a positive effect on hospital pharmaceutical development.

The geographical segmentation comprises the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. It is expected that North America will have the largest market share in the forecast period followed by Europe. It can also be predicted to be a significant contributor to the NSCLC market due to increased smoking habits in developing countries in the Asia Pacific region.

Increasing incidences of lung cancer associated with smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population growth are just a few of the growth factors of NSCLC.

Key players within global Non-Small Cell Lung Cancer market include Agennix AG, AstraZeneca, Eli Lily, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer and Roche amongst others.

The report segments global Non-Small Cell Lung Cancer market as follows:

Global Non-Small Cell Lung Cancer Market: Type Segment Analysis

  • Squamous cell (epidermoid) carcinoma
  • Adenocarcinoma
  • Large cell (undifferentiated) carcinoma
  • Other

Global Non-Small Cell Lung Cancer Market: Therapy Segment Analysis

  • Chemotherapy
  • Radiotherapy
  • Laser therapy
  • Photodynamic therapy (PDT)
  • Others

Global Non-Small Cell Lung Cancer Market: Distribution Channel Segment Analysis

  • Hospital pharmacies
  • Online pharmacies
  • Others

 Global Non-Small Cell Lung Cancer Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Non-Small Cell Lung Cancer Market, 2016 - 2025, (USD Million)
    • 2.2. Non-Small Cell Lung Cancer Market: Snapshot
  • Chapter 3. Global Non-Small Cell Lung Cancer Market - Industry Analysis
    • 3.1. Non-Small Cell Lung Cancer Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Wider availability of Treatment
    • 3.3. Restraints
      • 3.3.1. High Cost
    • 3.4. Opportunity
      • 3.4.1. Exploring new disease types
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Type Segment
      • 3.6.2. Market attractiveness analysis by Therapy Segment
      • 3.6.3. Market attractiveness analysis by Distribution Channel segment
      • 3.6.4. Market attractiveness analysis by regional segment
  • Chapter 4. Global Non-Small Cell Lung Cancer Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Non-Small Cell Lung Cancer market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Non-Small Cell Lung Cancer Market - Type Segment Analysis
    • 5.1. Global Non-Small Cell Lung Cancer market overview: by Type
      • 5.1.1. Global Non-Small Cell Lung Cancer market revenue share, by Type, 2018 and 2025
    • 5.2. Squamous cell (epidermoid) carcinoma
      • 5.2.1. Global Non-Small Cell Lung Cancer market by Squamous cell (epidermoid) carcinoma, 2016-2025 (USD Million)
    • 5.3. Adenocarcinoma
      • 5.3.1. Global Non-Small Cell Lung Cancer market by Adenocarcinoma, 2016-2025 (USD Million)
    • 5.4. Large cell (undifferentiated) carcinoma
      • 5.4.1. Global Non-Small Cell Lung Cancer market by Large cell (undifferentiated) carcinoma, 2016-2025 (USD Million)
    • 5.5. Other
      • 5.5.1. Global Non-Small Cell Lung Cancer market by Other, 2016-2025 (USD Million)
  • Chapter 6. Global Non-Small Cell Lung Cancer Market - Therapy Segment Analysis
    • 6.1. Global Non-Small Cell Lung Cancer market overview: by Therapy
      • 6.1.1. Global Non-Small Cell Lung Cancer market revenue share, by Therapy, 2018 and 2025
    • 6.2. Chemotherapy
      • 6.2.1. Global Non-Small Cell Lung Cancer market by Chemotherapy, 2016-2025 (USD Million)
    • 6.3. Radiotherapy
      • 6.3.1. Global Non-Small Cell Lung Cancer market by Radiotherapy, 2016-2025 (USD Million)
    • 6.4. Laser therapy
      • 6.4.1. Global Non-Small Cell Lung Cancer market by Laser therapy, 2016-2025 (USD Million)
    • 6.5. Photodynamic therapy (PDT)
      • 6.5.1. Global Non-Small Cell Lung Cancer market by Photodynamic therapy (PDT), 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Non-Small Cell Lung Cancer market by Others, 2016-2025 (USD Million)
  • Chapter 7. Global Non-Small Cell Lung Cancer Market - Distribution Channel Segment Analysis
    • 7.1. Global Non-Small Cell Lung Cancer market overview: by Distribution Channel
      • 7.1.1. Global Non-Small Cell Lung Cancer market revenue share, by Distribution Channel, 2018 and 2025
    • 7.2. Hospital pharmacies
      • 7.2.1. Global Non-Small Cell Lung Cancer market by Hospital pharmacies, 2016-2025 (USD Million)
    • 7.3. Online pharmacies
      • 7.3.1. Global Non-Small Cell Lung Cancer market by Online pharmacies, 2016-2025 (USD Million)
    • 7.4. Others
      • 7.4.1. Global Non-Small Cell Lung Cancer market by Others, 2016-2025 (USD Million)
  • Chapter 8. Global Non-Small Cell Lung Cancer Market - Regional Analysis
    • 8.1. Global Non-Small Cell Lung Cancer market overview: by region
      • 8.1.1. Global Non-Small Cell Lung Cancer market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Non-Small Cell Lung Cancer market, by country, 2016-2025 (USD Million)
      • 8.2.2. North America Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
      • 8.2.3. North America Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
      • 8.2.4. North America Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. U.S. Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.2.5.2. U.S. Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S. Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Non-Small Cell Lung Cancer market, by country, 2016-2025 (USD Million)
      • 8.3.2. Europe Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
      • 8.3.3. Europe Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
      • 8.3.4. Europe Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. UK Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.3.5.2. UK Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.3.5.3. UK Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.3.6.2. France Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.3.6.3. France Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.3.7.2. Germany Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.3.7.3. Germany Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.3.8.2. Rest of Europe Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Non-Small Cell Lung Cancer market, by country, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.4.5.2. China Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.4.5.3. China Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.4.6. France
        • 8.4.6.1. Japan Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.4.6.2. Japan Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.4.6.3. Japan Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.4.7.2. India Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.4.7.3. India Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Non-Small Cell Lung Cancer market, by country, 2016-2025 (USD Million)
      • 8.5.2. Latin America Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
      • 8.5.3. Latin America Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
      • 8.5.4. Latin America Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.5.5.2. Brazil Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
        • 8.5.6.2. Rest of Latin America Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million)
    • 8.6. Middle East & Africa
      • 8.6.1. Middle East and Africa Non-Small Cell Lung Cancer market, by country, 2016-2025 (USD Million)
      • 8.6.2. Middle East and Africa Non-Small Cell Lung Cancer market revenue, by Type, 2016-2025 (USD Million)
      • 8.6.3. Middle East and Africa Non-Small Cell Lung Cancer market revenue, by Therapy, 2016-2025 (USD Million)
      • 8.6.4. Middle East and Africa Non-Small Cell Lung Cancer market revenue, by Distribution Channel, 2016-2025 (USD Million) 
  • Chapter 10. Company Profiles
    • 10.1. Agennix AG
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Therapy Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. AstraZeneca
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Therapy Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Eli Lily
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Therapy Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. GlaxoSmithKline
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Therapy Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Merck & Co.
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Therapy Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Developments
    • 10.6. Novartis AG
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Therapy Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Developments
    • 10.7. Pfizer
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Therapy Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Developments
    • 10.8. Roche
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Therapy Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Developments

Methodology

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social